Botteman, Marc http://orcid.org/0000-0003-2808-7163
Nickel, Katharina
Corman, Shelby
Turini, Marco
Binder, Gary
Funding for this research was provided by:
Helsinn Therapeutics
Article History
Received: 21 February 2019
Accepted: 23 April 2019
First Online: 3 June 2019
Compliance with ethical standards
:
: This research is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors had full access to all data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. No potential author has been excluded/omitted from the authorship.
: Editorial assistance in the preparation of this article was provided by Catherine Mirvis of Pharmerit International under funding from Helsinn Therapeutics US, Inc.
: Marc Botteman is a shareholder of Pharmerit International. Shelby Corman, Katharina Nickel, and Marc Botteman are employees of Pharmerit International. Pharmerit received funding from Helsinn Therapeutics US, Inc., for study design, execution, analysis, and manuscript development. Marco Turini and Gary Binder are employees and shareholders of Helsinn Healthcare SA and Helsinn Therapeutics US, Inc., respectively. Helsinn Therapeutics US, Inc. commercializes AKYNZEO® (netupitant and palonosetron) in the US. AKYNZEO® (netupitant and palonosetron) is the subject of the present economic analysis.